“The emotional burden of removing interventions is already very heavy, and we are trying to spare the family the burden of yet another decision.” ID (led by @JeffLarnard & @WendyStead5) and Pall Care collab on perceptions & rx of antimicrobials around CMO
https://t.co/6GbSYTvsZq
Here again are my #Top10 Infectious Diseases papers of 2022. Not in order (alphabetical by first author). Non-COVID (because >120,000 COVID papers in 2022). Have to be at least one of: Paradigm Shifting, Practice Changing or Dogma Challenging #IDtwitter 🧵
@POTUS Expand it to Medicare B so they can get it at the doctor's office when they are WITH the doctor. Not having to go to yet ANOTHER place & get it at a (overworked) pharmacy
Fellowship interview season is upon us and we are so excited to meet applicants tomorrow for our very first interview day! Our fellowship has great things on the horizon and we can’t wait to share them with you #IDtwitter#IDFellows
🚨Here you go: What we know & don’t know about monkeypox, & how to think about the current outbreak.
One thing: It’s unique partly because it’s, er, happening amid a pandemic. Our reactions are deeply influenced by the last 3 years—in good & bad ways. 1/
https://t.co/SvEntsKEd3
Lots of options now for outpatient COVID therapy. Here’s our article that compares and contrasts efficacy vs cost per hospitalization prevented.
Paxlovid NNT 24 but cost/hosp/prevented is $$$.
3 dollar signs being a lot 😁
This week we have another @harvardmed Combined Rounds featuring a panel discussion on "Outpatient COVID-19 Therapies in the Time of Omicron." Panelists include Dan Taupin, MD (@dhtaupin) - Join us!
📅 Thurs. January 6
🕗 8 am
💻 https://t.co/fnUSdZAnUA
Come work with me! @BIDMChealth is hiring for an inpatient ID PharmD 👇🏼 Great colleagues, phenomenal trainees, & $5 Red Sox tickets. Plus, we can be BFFs! ☺️
@SIDPharm@accpinfdprn
https://t.co/WppetlPwZz